{
  "safetyreportversion": "2",
  "safetyreportid": "19529532",
  "primarysourcecountry": "DE",
  "occurcountry": "DE",
  "transmissiondateformat": "102",
  "transmissiondate": "20240410",
  "reporttype": "1",
  "serious": "1",
  "seriousnessdeath": "1",
  "seriousnesslifethreatening": "2",
  "seriousnesshospitalization": "2",
  "seriousnessdisabling": "2",
  "seriousnesscongenitalanomali": "2",
  "seriousnessother": "1",
  "receivedateformat": "102",
  "receivedate": "20210713",
  "receiptdateformat": "102",
  "receiptdate": "20240123",
  "fulfillexpeditecriteria": "1",
  "companynumb": "DE-PFIZER INC-2021817569",
  "duplicate": "1",
  "reportduplicate": [
    {
      "duplicatesource": "PFIZER INC",
      "duplicatenumb": "DE-PFIZER INC-2021805342"
    },
    {
      "duplicatesource": "PFIZER INC",
      "duplicatenumb": "JP-PFIZER INC-PV202400005237"
    }
  ],
  "primarysource": {
    "reportercountry": "DE",
    "qualification": "1",
    "literaturereference": "Ozdirik, B.. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.. Medicine. 2021;100 (24):e26377"
  },
  "sender": {
    "sendertype": "2",
    "senderorganization": "FDA-Public Use"
  },
  "receiver": {
    "receivertype": "6",
    "receiverorganization": "FDA"
  },
  "patient": {
    "patientonsetage": "70",
    "patientonsetageunit": "801",
    "patientsex": "2",
    "reaction": [
      {
        "reactionmeddraversionpt": "26.1",
        "reactionmeddrapt": "Encephalitis",
        "reactionoutcome": "5"
      },
      {
        "reactionmeddraversionpt": "26.1",
        "reactionmeddrapt": "Neurological symptom",
        "reactionoutcome": "5"
      },
      {
        "reactionmeddraversionpt": "26.1",
        "reactionmeddrapt": "Multiple organ dysfunction syndrome",
        "reactionoutcome": "5"
      },
      {
        "reactionmeddraversionpt": "26.1",
        "reactionmeddrapt": "Off label use",
        "reactionoutcome": "6"
      }
    ],
    "drug": [
      {
        "drugcharacterization": "1",
        "medicinalproduct": "BEVACIZUMAB",
        "drugauthorizationnumb": "761099",
        "drugstructuredosagenumb": "15",
        "drugstructuredosageunit": "007",
        "drugdosagetext": "15 MG/KG OVER 90 MINUTES",
        "drugindication": "Hepatocellular carcinoma",
        "actiondrug": "6",
        "drugadditional": "4",
        "activesubstance": {
          "activesubstancename": "BEVACIZUMAB"
        },
        "openfda": {
          "application_number": [
            "BLA761198",
            "BLA125085"
          ],
          "brand_name": [
            "AVZIVI TNJN",
            "AVASTIN"
          ],
          "generic_name": [
            "BEVACIZUMAB"
          ],
          "manufacturer_name": [
            "Bio-Thera Solutions, Ltd.",
            "Genentech, Inc."
          ],
          "product_ndc": [
            "82143-001",
            "82143-002",
            "50242-060",
            "50242-061"
          ],
          "product_type": [
            "HUMAN PRESCRIPTION DRUG"
          ],
          "route": [
            "INTRAVENOUS"
          ],
          "substance_name": [
            "BEVACIZUMAB-TNJN",
            "BEVACIZUMAB"
          ],
          "rxcui": [
            "2700735",
            "2700742",
            "2700744",
            "2700745",
            "1657066",
            "1657068",
            "1657073",
            "1657074"
          ],
          "spl_id": [
            "24041767-230c-9a58-e063-6394a90ad576",
            "8debebf6-af94-4ba7-8d67-c801f4ea27eb"
          ],
          "spl_set_id": [
            "a3976cf9-9edb-4ca2-9375-9bcd2e32f5b4",
            "939b5d1f-9fb2-4499-80ef-0607aa6b114e"
          ],
          "package_ndc": [
            "82143-001-01",
            "82143-002-01",
            "50242-060-01",
            "50242-060-10",
            "50242-061-01",
            "50242-061-10"
          ],
          "unii": [
            "2S9ZZM9Q9V"
          ],
          "nui": [
            "N0000193543",
            "N0000178291",
            "N0000193542"
          ],
          "pharm_class_epc": [
            "Vascular Endothelial Growth Factor Inhibitor [EPC]"
          ],
          "pharm_class_moa": [
            "Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]",
            "Vascular Endothelial Growth Factor Inhibitors [MoA]"
          ]
        }
      },
      {
        "drugcharacterization": "1",
        "medicinalproduct": "ATEZOLIZUMAB",
        "drugstructuredosagenumb": "1200",
        "drugstructuredosageunit": "003",
        "drugdosagetext": "1200 MG, OVER 2 HOURS",
        "drugindication": "Hepatocellular carcinoma",
        "actiondrug": "6",
        "drugadditional": "4",
        "activesubstance": {
          "activesubstancename": "ATEZOLIZUMAB"
        },
        "openfda": {
          "application_number": [
            "BLA761034"
          ],
          "brand_name": [
            "TECENTRIQ"
          ],
          "generic_name": [
            "ATEZOLIZUMAB"
          ],
          "manufacturer_name": [
            "Genentech, Inc."
          ],
          "product_ndc": [
            "50242-917",
            "50242-918"
          ],
          "product_type": [
            "HUMAN PRESCRIPTION DRUG"
          ],
          "route": [
            "INTRAVENOUS"
          ],
          "substance_name": [
            "ATEZOLIZUMAB"
          ],
          "rxcui": [
            "1792780",
            "1792785",
            "2119695",
            "2119696"
          ],
          "spl_id": [
            "f4fe4626-4d6c-4c50-9d52-51aae17f27d6"
          ],
          "spl_set_id": [
            "6fa682c9-a312-4932-9831-f286908660ee"
          ],
          "package_ndc": [
            "50242-917-01",
            "50242-917-86",
            "50242-918-01"
          ],
          "nui": [
            "N0000191260",
            "N0000191259",
            "M0556300",
            "M0001357",
            "M0001352"
          ],
          "pharm_class_epc": [
            "Programmed Death Receptor-1 Blocking Antibody [EPC]"
          ],
          "pharm_class_moa": [
            "Programmed Death Receptor-1-directed Antibody Interactions [MoA]"
          ],
          "pharm_class_cs": [
            "Antibodies, Monoclonal, Humanized [CS]",
            "Antibodies, Monoclonal [CS]",
            "Antibodies [CS]"
          ],
          "unii": [
            "52CMI0WC3Y"
          ]
        }
      }
    ]
  }
}